Th FDA wants to meet with the manufacturers of bile duct stents regarding their “off label” use for surgical applications. The stents are the latest drug or medical device to draw the attention of the FDA for inappropriate, or at least, unapproved use. The unapproved or off label uses comes as a direct result of the companies’ overly aggressive marketing tactics.
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.